AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06306651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional oxygen therapy group
Description: Patients who will be randomized to simple oxygen mask therapy. The simple face mask will be applied in a rate range between 6-10 L/min.
Study NCT03867786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete an acute exercise visit.
Study NCT03867786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Control
Description: Participants will complete a video control visit.
Study NCT06259591 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer follow-up
Description: The daily step count will be obtained from the patients using a pedometer app (OutWalk) from day 8 to day 30 after surgery.
Study NCT06259591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer follow-up
Description: The daily step count will be obtained from the patients using a pedometer app (OutWalk) from day 8 to day 30 after surgery.
Study NCT06259591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulation coaching
Description: Patients will receive coaching text messages every Monday, Wednesday and Friday between day 8 and day 30 after surgery, based on a pre-fixed template.
Study NCT06482762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainSonix Pulsar 1002
Description: Device that delivers low intensity focused ultrasound
Study NCT05211921 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Multi-Gyn ActiGel Plus
Description: vaginal gel
Study NCT05919381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentuximab Injection
Description: Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
Study NCT05919381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gentuximab Injection
Description: Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
Study NCT05919381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentuximab Injection Placebo
Description: Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
Study NCT05919381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gentuximab Injection Placebo
Description: Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
Study NCT06322368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofunctional and respiratory training program
Description: The patients will receive exercises included in a myofunctional approach and a respiratory training focused on inspiratory and expiratory muscles using a device.
Study NCT06322368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Range of motion and thermal and mechanical stimulation exercising
Description: The patients will receive the standard treatment of speech and language therapy including range of motion exercises (open and close the mouth) and thermal and mechanical stimulation in the orofacial region.
Study NCT05144880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213416
Description: Tobacco Flavor
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213422
Description: Tobacco Flavor
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213716
Description: Tobacco Flavor
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213722
Description: Tobacco Flavor
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1211216
Description: Menthol Flavor
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1211222
Description: Menthol Flavor
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213616
Description: Menthol Flavor
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213622
Description: Menthol Flavor
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213816
Description: NTNM Flavor
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213822
Description: NTNM Flavor
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1211916
Description: NTNM Flavor
Study NCT05960305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1211922
Description: NTNM Flavor
Study NCT05501574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Inhalation Powder
Description: Tacrolimus powder for inhalation to prevent acute allograft rejection
Study NCT05501574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plastiape RS00 Dry Powder inhaler device
Description: dry powder inhaler device
Study NCT06124612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombotic assessment
Description: GTT~The Global Thrombosis Test (GTT) (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~TEG Thromboelastography (TEG, Haemonetics Corporation, USA) is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Citrated plasma will be stored for subsequent evaluation of thrombosis and fibrinolysis markers (including but not restricted to D-dimer, PAI-1, hs-CRP, NETs)
Study NCT05219084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hip denervation
Description: Lidocaine 2% 2ml was injected into each genicular nerve
Study NCT05219084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular hydration
Description: 10 ml; of normal; saline were injected inside the hip joint
Study NCT05219084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined group
Description: hip denervation and intra-articular hydration were conducted together
Study NCT05219084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Normal; saline was injected subcutaneously
Study NCT05281445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tic suppression task
Description: Tic Suppression Task (TST, administered to Tourette syndrome participants only): At the beginning of the task, the child participant will be seated alone in front of a computer monitor with a countdown timer visible on the screen. For the first 10 minutes (baseline condition) they will be asked to tic freely and not to try to suppress their tics. For the second 10 minutes children will be asked to suppress their tics and will receive points for successful suppression. Participants will then be asked to sit alone in the room and tic freely for an additional 10-minutes.
Study NCT05642754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overall uncertainty language
Description: Researchers are testing different forms of information about overall study uncertainty and margin of error around main result
Study NCT05642754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Overall uncertainty language
Description: Researchers are testing different forms of information about overall study uncertainty and margin of error around main result
Study NCT06223451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that can alter the excitability of the motor area by generating a magnetic field through a coil. Low-frequency stimulation (\<1 Hz) applied with rTMS has inhibitory effects. Repetitive transcranial magnetic stimulation has a neurorehabilitative role as it can modulate the excitability of targeted brain areas. Inhibitory repetitive transcranial magnetic stimulation will be applied to 11 patients with unilateral neglect due to ischemic stroke under the supervision of a doctor for a total of 10 sessions over 2 weeks with conventional rehabilitation.Each session will last for 20 minutes,total of 1200 pulses, 1 Hz repetitive transcranial manyetic stimulation over the unaffected left posterior parietal cortex.
Study NCT06223451 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: Patients in the sham group will receive sham transcranial magnetic stimulation with sham coil for 20 minutes a day, 10 sessions in total, together with conventional rehabilitation.
Study NCT05785533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: App that provides recovery guidance based on pain and functional outcomes
Study NCT05785533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Paper based discharge instruction that provide information on pain management
Study NCT05899608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivonescimab Injection
Description: Subject will receive ivonescimab and chemotherapy as an IV injection
Study NCT05899608 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab Injection
Description: Subject will receive pembrolizumab and chemotherapy as an IV injection
Study NCT06189703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tRNS
Description: transcranial random noise stimulation applied to the right IFG and the left DLPFC
Study NCT06189703 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tRNS
Description: transcranial random noise stimulation applied to the right IFG and the left DLPFC
Study NCT06067048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Oral Capsule
Description: 36 cycles (1 cycle is 28 days)
Study NCT04698785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment by regorafenib and best supportive care
Description: Treatment for 13 cycles (12 months) maximum.~During each cycle :~* patients ≥ 16 years old and patients \<16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.~* patients \< 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Regorafenib, during 21 days, followed by 7 days without treatment
Study NCT05961969 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic surgery
Description: 1. Patients with rectal cancer.~2. Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis
Study NCT06465303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTP-026
Description: Intervention is for each subject administered as three 30-minutes infusions of either A: 25μg/kg RTP-026; or B: ≥ 26μg/kg and ≤75μg/kg RTP-026; or C: A maximum of 3 x treatment dose RTP-026 as given in B;
Study NCT06465303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention is for each subject administered as three 30-minutes infusions of placebo
Study NCT05569538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.
Study NCT06464744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Intermittent Theta burst stimulation will be delivered on the on the primary motor cortex using a figure-of-eight coil, supported by neuronavigation. The stimulation intensity will be set to 90% of the motor threshold
Study NCT06464744 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stimulation using a placebo coil
Description: The placebo coil looks identical to the active coil but it only delivers skin tingling and no active brain stimulation.
Study NCT05297279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home delivery Omega-3 rich Food
Description: The active treatment arm will receive voucher (with a specified amount) weekly home delivery omega-3 rich food for the 12-weeks (3 months) intervention. Participants will be limited to purchasing foods rich in omega-3 only.
Study NCT05297279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Motivational Coaching
Description: The active treatment arm will receive weekly personalize dietary couching by a dietary coach on omega-3 rich food for the 12-weeks intervention. Participant will also receive educational materials and guidance about what kind of food to order, how to cook, prepare (recipes) and store omega-3 rich foods.
Study NCT05297279 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home delivery Food
Description: The control treatment arm will receive voucher (with a specified amount) weekly home delivery food (any kind of food) for the 12-weeks (3 months) intervention. Participant will not receive dietary coaching on food choices and will not be limited to purchasing foods rich in omega-3.
Study NCT06599983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program, Educational Storytelling, an Educational Program Against Child Abuse and Neglect.
Description: One day educational program, aiming at increase dental personnels attitude, knowledge and behaviour in regard to detect and report child abuse and neglect, and to treat patients with known and unknown history of child abuse and neglect.
Study NCT05074888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prospekta
Description: Oral administration.
Study NCT05074888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study NCT06605794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeFlow percutaneous atrial septal shunt
Description: The trial devices included a percutaneous atrial septal shunt and an atrial septal shunt delivery system. The specifications of the atrial septal shunt device were -φ5, φ7, φ9, φ11, and the specifications of the atrial septal shunt delivery system-FFISS-B were 9F and 10F.
Study NCT06607367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (JAKAVI®)
Description: Initial starting dose will be 10mg BD
Study NCT06607367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag (Revolade®)
Description: Initial starting dose will be 50mg daily
Study NCT06606418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture group
Description: The patients in this group received acupuncture treatment 3 times a week for 4 weeks. Acupuncture points selection: bilateral Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), Shangqiu (SP5), Yin Bai (SP5), foot Qioyin (GB44), Li Dui (ST45). Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to skew 0.5\~0.8 inches at the back acupoint, 0.5\~0.8 inches at Shangqiu (SP5), 0.1 inches at Yin Bai (SP5), foot Qiaoyin (GB44) and Li Dui (ST45), and left the needle for 30 minutes to wait for qi.
Study NCT06606418 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture group
Description: The patients in this group received sham acupuncture treatment 3 times a week for 4 weeks. Sham acupuncture points are selected at sham points close to the acupoints of the acupuncture group: 3 inches beside Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), 1 inches below Shangqiu (SP5), 0.1 inches behind the middle edge of the great toe, second toe and fourth toenail of the foot. Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to pierce the skin shallowly, and left the needle for 30 minutes.
Study NCT06608836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: an ice massage
Description: an ice massage
Study NCT06608836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the cold spray
Description: the cold spray
Study NCT06607861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline group
Description: nebulization of 4 mL 0.9% saline twice daily
Study NCT06607861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine group
Description: nebulization of 1 µg/kg dexmedetomidine diluted in 4 mL 0.9% saline twice daily
Study NCT06607861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine group
Description: bilateral nebulization (60 mg) using a mucosal atomization device twice daily
Study NCT06605001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delay of Gratification
Description: Children will complete a delay of gratification task with 1 of 2 rewards
Study NCT05766631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DynamiCare Health
Description: Participants earn incentives for:~1. CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants.~2. Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone).~3. Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records.~4. The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment.
Study NCT05766631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Treatment-As-Usual
Description: Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
Study NCT05766631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone Treatment-As-Usual
Description: Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
Study NCT06761443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The experimental phase of this study had last 8 weeks and each patient will make 3 visits (week 0, week 4, week 8).
Study NCT06761443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The experimental phase of this study had last 8 weeks and each patient will make 3 visits (week 0, week 4, week 8).
Study NCT06762067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: Participants will undergo physiotherapy exercises in a mirror alongside post-surgery care. The program includes palming exercises, eye exercises, pencil push-ups, Brock string exercises, thumb exercises, and proprioceptive neuromuscular facilitation exercises. The first exercise warms up extra ocular muscles, the second improves eye coordination, the third motivates the lazy eye, the fourth strengthens eye muscles, and the fifth involves a near-distance jump for oblique muscles.
Study NCT06762067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: The patients within the control group will receive traditional care post-strabismus operation as eye glasses and eye drops and regular exercise
Study NCT05746650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles
Study NCT05746650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone (somatropin)
Description: Daily injection of growth hormone
Study NCT05746650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth hormone (somatropin)
Description: Daily injection of growth hormone